SEC Comment Letter 0000000000-24-007140 to GT Biopharma, Inc. (GTBP)
GT Biopharma, Inc.
Date: June 24, 2024 · CIK: 0000109657 · Accession: 0000000000-24-007140
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-280326
Letter
United States securities and exchange commission logo June 24, 2024 Michael Breen Interim Chief Executive Officer GT Biopharma, Inc. 9350 Wilshire Blvd. Suite 203 Beverly Hills, CA 90212 Re:GT Biopharma, Inc. Registration Statement on Form S-1 Filed June 20, 2024 File No. 333-280326 Dear Michael Breen: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tim Buchmiller at 202-551-3635 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Roger W. Bivans, Esq.
Show Raw Text
United States securities and exchange commission logo
June 24, 2024
Michael Breen
Interim Chief Executive Officer
GT Biopharma, Inc.
9350 Wilshire Blvd. Suite 203
Beverly Hills, CA 90212
Re:GT Biopharma, Inc.
Registration Statement on Form S-1
Filed June 20, 2024
File No. 333-280326
Dear Michael Breen:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Tim Buchmiller at 202-551-3635 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Roger W. Bivans, Esq.